United Therapeutics (UTHR) revenue breakdown
By product, Tyvaso DPI is the largest at 41% of fiscal 2025 revenue, growing 101% a year over 3 years.
By region, United States is the largest at 95% of fiscal 2025 revenue, growing 17% a year over 5 years.
Revenue by product
Fiscal years, as United Therapeutics reports them in its 10-K filings; fiscal 2025 total $3.2B.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Tyvaso DPI | — | — | $158M | $731M | $1.0B | $1.3B | 41% |
| Nebulized Tyvaso | — | — | $715M | $503M | $587M | $586M | 18% |
| Remodulin | $517M | $514M | $500M | $495M | $538M | $527M | 17% |
| Orenitram | $293M | $306M | $325M | $359M | $434M | $497M | 16% |
| Unituxin | $123M | $202M | $183M | $199M | $239M | $227M | 7% |
| Adcirca | $67M | $56M | $41M | $29M | $24M | $30M | 1% |
| Other | — | — | $14M | $12M | $22M | $24M | 1% |
| Tyvaso | — | $608M | — | — | — | — | — |
| Tyvaso | $483M | — | — | — | — | — | — |
Revenue by region
Fiscal years, as United Therapeutics reports them in its 10-K filings; fiscal 2025 total $3.2B.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| United States | $1.4B | $1.6B | $1.8B | $2.2B | $2.7B | $3.0B | 95% |
| Rest-of-World | $71M | $121M | $122M | $125M | $138M | $146M | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for UTHR.
Open UTHR in InvestinglyQuestions
Where does United Therapeutics make its money?
In fiscal 2025, by product: Tyvaso DPI $1.3B, Nebulized Tyvaso $586M, Remodulin $527M, Orenitram $497M, Unituxin $227M.
From United Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.